| 2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir+ Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies. A Oglesby, K Angelis, Y Punekar, V Chounta, A Antela, J Matthews, ... Open Forum Infectious Diseases 6, 2019 | 2 | 2019 |
| 319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+ RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks L Kahl, GA McComsey, M Coronado Poggio, S Lupo, J de Wet, DA Parks, ... Open Forum Infectious Diseases 6 (Supplement_2), S169-S170, 2019 | | 2019 |
| 75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load> 500,000 c/mL: 48-Week Subgroup Analysis of the STAT … CPM Rolle, M Berhe, T Singh, R Ortiz, AK Wurapa, M Ramgopal, ... Open Forum Infectious Diseases 8 (Supplement_1), S49-S49, 2021 | 3 | 2021 |
| An evaluation of different partitioning strategies for Bayesian estimation of species divergence times K Angelis, S Álvarez-Carretero, M Dos Reis, Z Yang Systematic Biology 67 (1), 61-77, 2018 | 37 | 2018 |
| Bayesian estimation of nonsynonymous/synonymous rate ratios for pairwise sequence comparisons K Angelis, M Dos Reis, Z Yang Molecular Biology and Evolution 31 (7), 1902-1913, 2014 | 17 | 2014 |
| Bayesian statistical modelling of genetic sequence evolution K Angelis UCL (University College London), 2016 | | 2016 |
| Bone, renal, and inflammatory biomarkers up to week 100 post switch to DTG+ RPV: the SWORD-1 and SWORD-2 studies B Hernandez, L Kahl, J Matthews, T Vincent, K Angelis, J Koteff HIV & Hepatitis Nordic Conference, 26-28, 2018 | 9 | 2018 |
| Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir+ rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and … J Van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 85 (3), 325-330, 2020 | 47 | 2020 |
| Comparison of viral replication below 50 copies/mL for two-drug (DTG+ RPV) versus three-drug current antiretroviral regimen (CAR) therapy in the SWORD-1 and SWORD-2 studies … M Underwood, K Angelis, R Wang, B Wynne, EA Blair, LP Kahl, T Vincent, ... Proceedings of the HIV Drug Therapy, Glasgow, 2018 | 5 | 2018 |
| Comparison of viral replication for two-drug (DTG plus RPV) versus three-drug current antiretroviral regimen (CAR) in the SWORD-1 and SWORD-2 studies R Wang, M Underwood, J Koteff, K Angelis, B Wynne, E Blair, L Kahl, ... JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21, 2018 | | 2018 |
| Dating the origin of hepatitis B virus reveals higher substitution rate and adaptation on the branch leading to F/H genotypes D Paraskevis, K Angelis, G Magiorkinis, E Kostaki, SYW Ho, A Hatzakis Molecular Phylogenetics and Evolution 93, 44-54, 2015 | 45 | 2015 |
| Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... Oxford University Press, 2019 | 23 | 2019 |
| Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial KE Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... Clinical Infectious Diseases 70 (4), 549-556, 2020 | 94 | 2020 |
| Dolutegravir-Based Antiretroviral Therapy for the Treatment of Patients Co-Infected with Tuberculosis and HIV: A Multicenter, Phase 3B, Noncomparative, Open-Label, Randomized Trial K Dooley, R Kaplan, N Mwelase, B Grinsztejn, E Ticona, M Lacerda, ... | | 2018 |
| Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV CP Rolle, M Berhe, T Singh, R Ortiz, A Wurapa, M Ramgopal, PA Leone, ... Aids 35 (12), 1957-1965, 2021 | 39 | 2021 |
| Durable suppression and low rate of virologic failures 3 years after switch to DTG+ RPV 2DRug Regimen: SWORD 1 and 2 Studies J van Wyk, C Orkin, R Rubio, J Bogner, D Baker, MA Khuong-Josses, ... 25th Annual Conference of the British HIV Association, 2-5, 2019 | 9 | 2019 |
| Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies J Van Wyk, C Orkin, R Rubio-Garcia, J Bogner, D Baker, ... HIV MEDICINE 20, 18-19, 2019 | 2 | 2019 |
| Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 … M Aboud, C Orkin, D Podzamczer, JR Bogner, D Baker, ... The lancet HIV 6 (9), e576-e587, 2019 | 126 | 2019 |
| Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 … JM Llibre, CC Hung, C Brinson, F Castelli, PM Girard, LP Kahl, EA Blair, ... The Lancet 391 (10123), 839-849, 2018 | 403 | 2018 |
| Feasibility, efficacy, and safety of using dolutegravir/lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV … CP Rolle, M Berhe, T Singh, R Ortiz, A Wurapa, M Ramgopal, PA Leone, ... INFECTION 49 (SUPPL 1), S13-S14, 2021 | | 2021 |